PUBLISHER: The Business Research Company | PRODUCT CODE: 1826841
PUBLISHER: The Business Research Company | PRODUCT CODE: 1826841
Vaginal And Vulval Inflammatory Disease Treatment Global Market Report 2025
Vaginal and vulval inflammatory diseases encompass a group of conditions marked by inflammation of the vaginal and vulvar tissues, which may result in symptoms such as irritation, swelling, pain, redness, and sometimes infection. These conditions are commonly caused by bacterial, viral, or fungal infections, allergic reactions, skin disorders, or autoimmune diseases. Treatment generally involves addressing the root cause of the condition and managing symptoms through appropriate medical treatments and lifestyle changes.
The primary indications for treating vaginal and vulval inflammatory diseases include vaginal dryness, vaginal burning, vaginal discharge, genital itching, recurrent urinary tract infections, urinary incontinence, and other related issues. Vaginal dryness, often linked to reduced moisture in the vaginal area, is typically caused by hormonal changes, such as those seen during menopause. Treatment options include anti-itch medications, corticosteroid ointments, and emollients, and these are utilized by various end-users, including hospital pharmacies, specialty clinics, and other healthcare providers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The vaginal and vulval inflammatory diseases treatment market research report is one of a series of new reports from The Business Research Company that provides vaginal and vulval inflammatory diseases treatment market statistics, including the vaginal and vulval inflammatory diseases treatment industry global market size, regional shares, competitors with the vaginal and vulval inflammatory diseases treatment market share, detailed vaginal and vulval inflammatory diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the vaginal and vulval inflammatory diseases treatment industry. This dark store market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vaginal and vulval inflammatory disease treatment market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.05 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising cases of vaginal infections, growing awareness about women's health, improving healthcare infrastructure, an aging population, and increasing urbanization.
The vaginal and vulval inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing awareness of vulvovaginal health, rising demand for non-invasive treatments, rising incidence of chronic inflammatory diseases, increasing access to healthcare, and a growing number of healthcare professionals. Major trends in the forecast period include technological advancements in diagnostic tools, integration of artificial intelligence (AI) in diagnostics, home-based care solutions, development of vaginal vaccines, and minimally invasive surgical techniques.
The forecast of 6.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of topical immunosuppressants and microbiome-based therapies sourced from Canada and France, exacerbating out-of-pocket costs and limiting chronic condition management. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rise in diabetes cases is anticipated to fuel the expansion of the vaginal and vulval inflammatory disease treatment market. Diabetes is a chronic condition marked by high blood sugar levels due to the body's inability to produce or use insulin properly. The growing prevalence of diabetes can be linked to factors such as sedentary lifestyles, poor eating habits, increasing obesity, genetic factors, and an aging population. Treatments for vaginal and vulval inflammatory diseases help diabetes patients by reducing recurrent infections, which are frequent due to high blood sugar and compromised immune function, while also improving insulin sensitivity and overall blood sugar management. For example, in March 2024, the Office for Health Improvement & Disparities in the UK reported a 22% increase in individuals with type 1 diabetes receiving all recommended care processes from March 2022 to March 2023, and a 21% increase for type 2 diabetes. Additionally, 37.9% achieved target HbA1c levels, the highest ever recorded by the National Diabetes Audit (NDA). As a result, the growing incidence of diabetes is driving the growth of the vaginal and vulval inflammatory disease treatment market.
Key players in the vaginal and vulval inflammatory disease treatment market are focusing on the development of innovative products, such as vaginal synbiotics, to improve treatment effectiveness and patient outcomes. A vaginal synbiotic is a combination of probiotics and prebiotics designed to support the vaginal microbiome, maintain balance, and prevent infections. For example, in May 2024, Seed Health Inc., a biotechnology company based in the US, launched VS-01, a pioneering product intended to transform vaginal care. This first-of-its-kind product is scientifically formulated to promote vaginal health by supporting microbiome balance. VS-01 uses a proprietary blend of probiotics that target the vaginal microbiome, helping to preserve its natural defenses. By utilizing advanced microbiome science, this product addresses imbalances and discomfort, offering a comprehensive solution for women aiming to improve vaginal health.
In March 2023, GSK plc, a pharmaceutical company from the UK, entered into an exclusive partnership with SCYNEXIS Inc. to license and commercialize Brexafemme (ibrexafungerp). Through this collaboration, GSK plc seeks to expand its infectious disease portfolio by marketing Brexafemme for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC, as well as advancing its development for invasive candidiasis. This partnership addresses the growing demand for effective antifungal treatments. SCYNEXIS Inc., a US-based company, specializes in treatments for vulvovaginal candidiasis (VVC).
Major players in the vaginal and vulval inflammatory disease treatment market are Pfizer Incorporated, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hologic Inc., Ferring Pharmaceuticals, Venus Concept Inc., Kyung Hee University Medical Center, Duchesnay Inc., Evofem Biosciences Inc., SEID Lab, Curive Healthcare Inc., Replens, MC2 Therapeutics ApS, FemiClear.
North America was the largest region in the vaginal and vulval inflammatory disease treatment market in 2024. The regions covered in vulval inflammatory disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaginal and vulval inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vaginal and vulval inflammatory disease treatment market includes revenues earned by entities by providing services diagnostic services, pharmaceutical treatment services, and therapeutic procedures and related products such as antifungal creams, antibiotics, anti-inflammatory medications, hormonal therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vaginal And Vulval Inflammatory Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vaginal and vulval inflammatory disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vaginal and vulval inflammatory disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vaginal and vulval inflammatory disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Indication: Vaginal Dryness; Vaginal Burning; Vaginal Discharge; Genital Itching; Recurrent Urinary Tract Infections; Urinary Incontinence; Other Indications
- 2) By Treatment: Anti-Itch Medications; Corticosteroid Ointments; Anti-Itch Emollients
- 3) By End User: Hospital Pharmacies; Specialty Clinics; Other End-Users
- Subsegments:
- 1) By Vaginal Dryness: Hormonal Therapy; Non-Hormonal Moisturizers; Lubricants and Topical Agents
- 2) By Vaginal Burning: Anti-inflammatory Creams and Gels; Topical Steroids; Pain Relief Medications
- 3) By Vaginal Discharge: Antifungal Treatments; Antibacterial Treatments; Probiotics and Prebiotics
- 4) By Genital Itching: Antihistamines; Topical Corticosteroids; Antifungal Treatments
- 5) By Recurrent Urinary Tract Infections (UTIs): Antibiotics; Probiotics; Cranberry-based Supplements
- 6) By Urinary Incontinence: Behavioral Therapy; Medications (Anticholinergics, Beta-3 Agonists); Surgical Interventions
- 7) By Other Indications: Lichen Sclerosus; Vaginal Atrophy; Pelvic Floor Dysfunction; Vulvar Vestibulitis
- Companies Mentioned: Pfizer Incorporated; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Teva Pharmaceutical Industries Limited; Sandoz International GmbH; Hologic Inc.; Ferring Pharmaceuticals; Venus Concept Inc.; Kyung Hee University Medical Center; Duchesnay Inc.; Evofem Biosciences Inc.; SEID Lab; Curive Healthcare Inc.; Replens; MC2 Therapeutics ApS; FemiClear
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vaginal And Vulval Inflammatory Disease Treatment Market Characteristics
3. Vaginal And Vulval Inflammatory Disease Treatment Market Trends And Strategies
4. Vaginal And Vulval Inflammatory Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Vaginal And Vulval Inflammatory Disease Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Vaginal And Vulval Inflammatory Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Vaginal And Vulval Inflammatory Disease Treatment Market Growth Rate Analysis
- 5.4. Global Vaginal And Vulval Inflammatory Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Vaginal And Vulval Inflammatory Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Vaginal And Vulval Inflammatory Disease Treatment Total Addressable Market (TAM)
6. Vaginal And Vulval Inflammatory Disease Treatment Market Segmentation
- 6.1. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Vaginal Dryness
- Vaginal Burning
- Vaginal Discharge
- Genital Itching
- Recurrent Urinary Tract Infections
- Urinary Incontinence
- Other Indications
- 6.2. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-Itch Medications
- Corticosteroid Ointments
- Anti-Itch Emollients
- 6.3. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Specialty Clinics
- Other End-Users
- 6.4. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Dryness, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hormonal Therapy
- Non-Hormonal Moisturizers
- Lubricants and Topical Agents
- 6.5. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Burning, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-inflammatory Creams and Gels
- Topical Steroids
- Pain Relief Medications
- 6.6. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Vaginal Discharge, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antifungal Treatments
- Antibacterial Treatments
- Probiotics and Prebiotics
- 6.7. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Genital Itching, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antihistamines
- Topical Corticosteroids
- Antifungal Treatments
- 6.8. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Recurrent Urinary Tract Infections (UTIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antibiotics
- Probiotics
- Cranberry-based Supplements
- 6.9. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Urinary Incontinence, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Behavioral Therapy
- Medications (Anticholinergics, Beta-3 Agonists)
- Surgical Interventions
- 6.10. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lichen Sclerosus
- Vaginal Atrophy
- Pelvic Floor Dysfunction
- Vulvar Vestibulitis
7. Vaginal And Vulval Inflammatory Disease Treatment Market Regional And Country Analysis
- 7.1. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Vaginal And Vulval Inflammatory Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market
- 8.1. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Vaginal And Vulval Inflammatory Disease Treatment Market
- 9.1. China Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 9.2. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Vaginal And Vulval Inflammatory Disease Treatment Market
- 10.1. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Vaginal And Vulval Inflammatory Disease Treatment Market
- 11.1. Japan Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 11.2. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Vaginal And Vulval Inflammatory Disease Treatment Market
- 12.1. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market
- 13.1. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market
- 14.1. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 14.2. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market
- 15.1. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 15.2. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Vaginal And Vulval Inflammatory Disease Treatment Market
- 16.1. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Vaginal And Vulval Inflammatory Disease Treatment Market
- 17.1. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Vaginal And Vulval Inflammatory Disease Treatment Market
- 18.1. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Vaginal And Vulval Inflammatory Disease Treatment Market
- 19.1. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Vaginal And Vulval Inflammatory Disease Treatment Market
- 20.1. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market
- 21.1. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 21.2. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Vaginal And Vulval Inflammatory Disease Treatment Market
- 22.1. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Vaginal And Vulval Inflammatory Disease Treatment Market
- 23.1. North America Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 23.2. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Vaginal And Vulval Inflammatory Disease Treatment Market
- 24.1. USA Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 24.2. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Vaginal And Vulval Inflammatory Disease Treatment Market
- 25.1. Canada Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 25.2. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Vaginal And Vulval Inflammatory Disease Treatment Market
- 26.1. South America Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 26.2. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market
- 27.1. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market
- 28.1. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 28.2. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Vaginal And Vulval Inflammatory Disease Treatment Market
- 29.1. Africa Vaginal And Vulval Inflammatory Disease Treatment Market Overview
- 29.2. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Vaginal And Vulval Inflammatory Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Landscape And Company Profiles
- 30.1. Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Landscape
- 30.2. Vaginal And Vulval Inflammatory Disease Treatment Market Company Profiles
- 30.2.1. Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Vaginal And Vulval Inflammatory Disease Treatment Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Eli Lilly and Company
- 31.3. Teva Pharmaceutical Industries Limited
- 31.4. Sandoz International GmbH
- 31.5. Hologic Inc.
- 31.6. Ferring Pharmaceuticals
- 31.7. Venus Concept Inc.
- 31.8. Kyung Hee University Medical Center
- 31.9. Duchesnay Inc.
- 31.10. Evofem Biosciences Inc.
- 31.11. SEID Lab
- 31.12. Curive Healthcare Inc.
- 31.13. Replens
- 31.14. MC2 Therapeutics ApS
- 31.15. FemiClear
32. Global Vaginal And Vulval Inflammatory Disease Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Vaginal And Vulval Inflammatory Disease Treatment Market
34. Recent Developments In The Vaginal And Vulval Inflammatory Disease Treatment Market
35. Vaginal And Vulval Inflammatory Disease Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Vaginal And Vulval Inflammatory Disease Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
